HC Wainwright Begins Coverage on Aileron Therapeutics (ALRN)

Share on StockTwits

HC Wainwright began coverage on shares of Aileron Therapeutics (NASDAQ:ALRN) in a research report report published on Monday, Marketbeat reports. The firm issued a buy rating and a $7.00 target price on the stock.

Several other analysts also recently weighed in on ALRN. Zacks Investment Research upgraded Aileron Therapeutics from a hold rating to a buy rating and set a $0.75 target price for the company in a research note on Thursday, December 27th. ValuEngine downgraded Aileron Therapeutics from a buy rating to a hold rating in a research note on Thursday, January 24th.

Shares of NASDAQ:ALRN opened at $1.92 on Monday. Aileron Therapeutics has a twelve month low of $0.52 and a twelve month high of $9.50. The company has a market cap of $27.73 million, a P/E ratio of -1.08 and a beta of 3.18. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.19.

A number of institutional investors have recently bought and sold shares of the business. Bridgeway Capital Management Inc. raised its holdings in Aileron Therapeutics by 78.6% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock valued at $312,000 after acquiring an additional 50,000 shares in the last quarter. Vanguard Group Inc raised its holdings in Aileron Therapeutics by 8.0% in the 3rd quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock valued at $265,000 after acquiring an additional 7,109 shares in the last quarter. Parkwood LLC acquired a new position in Aileron Therapeutics in the 3rd quarter valued at approximately $149,000. Finally, Renaissance Technologies LLC acquired a new position in Aileron Therapeutics in the 3rd quarter valued at approximately $137,000. 9.16% of the stock is owned by hedge funds and other institutional investors.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

See Also: Earnings Reports

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.